Cancer drug trial pulled before it even started
NCT ID NCT04372641
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This was a phase I trial testing a new drug called CB-5339 in people with advanced solid tumors or lymphomas. The drug was designed to block certain enzymes that cancer cells need to grow. However, the study was withdrawn before enrolling any participants, so no results or safety data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CB-5339 (a p97 inhibitor taken by mouth)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Vaccine trains immune system to hunt down cancer cells
- Gut radiation may revive immunotherapy in resistant cancers
- One shot: could a single radiation dose control metastatic cancer?
- Can talking about stress ease Cancer's mental toll? new study aims to find out
- Mayo clinic hunts for hidden cancer clues in DNA and proteins